Skip to content

Clinical trials

Observational Diabetes Mellitus, Type 1 trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 1 Phase: Observational Country / region: Canada Clear all

42 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20072
20082
20101
20123
20142
20151
20162
20172
20182
20194
20204
20212
20225
20232
20243
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed24
Recruiting7
Terminated4
Unknown status3
Withdrawn1
Not yet recruiting1
Suspended1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S4
Institut de Recherches Cliniques de Montreal3
LMC Diabetes & Endocrinology Ltd.3
Laval University3
McGill University Health Centre/Research Institute of the McGill University Health Centre3
CHU de Quebec-Universite Laval2
Children's Hospital of Eastern Ontario2
University of British Columbia2
University of Calgary2
Bayer1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 142
Diabetes Mellitus14
Diabetes Mellitus, Type 212
Cardiovascular Diseases3
Diabetic Neuropathies2
Feeding and Eating Disorders2
Hypoglycemia2
Insulin Resistance2
Renal Insufficiency, Chronic2
Autoimmune Diseases1

Trials

Showing 1 to 25 of 42. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.